AKT1 is altered in 1.33% of gastric adenocarcinoma patients [2].

AKT1 is an inclusion eligibility criterion in 2 clinical trials for gastric adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain AKT1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].

AKT2 is altered in 0.76% of gastric adenocarcinoma patients [2].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains AKT2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

AKT3 is altered in 1.02% of gastric adenocarcinoma patients [2].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains AKT3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ALK is altered in 2.4% of gastric adenocarcinoma patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

APC is altered in 6.55% of gastric adenocarcinoma patients [2].

APC is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains APC status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ARID1A is altered in 18.64% of gastric adenocarcinoma patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATM is altered in 6.84% of gastric adenocarcinoma patients [2].

ATM is an inclusion eligibility criterion in 5 clinical trials for gastric adenocarcinoma, of which 5 are open and 0 are closed. Of the trials that contain ATM status and gastric adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 3 are phase 2 (3 open) [3].

ATR is altered in 1.55% of gastric adenocarcinoma patients [2].

ATR is an inclusion eligibility criterion in 2 clinical trials for gastric adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATR status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BARD1 is altered in 1.5% of gastric adenocarcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 3 clinical trials for gastric adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain BARD1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

BRAF is altered in 2.37% of gastric adenocarcinoma patients [2].

BRAF is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA1 is altered in 1.98% of gastric adenocarcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 5 clinical trials for gastric adenocarcinoma, of which 5 are open and 0 are closed. Of the trials that contain BRCA1 status and gastric adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 3 are phase 2 (3 open) [3].

BRCA2 is altered in 6.39% of gastric adenocarcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 5 clinical trials for gastric adenocarcinoma, of which 5 are open and 0 are closed. Of the trials that contain BRCA2 status and gastric adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 3 are phase 2 (3 open) [3].

BRIP1 is altered in 1.67% of gastric adenocarcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 3 clinical trials for gastric adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRIP1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

BTRC is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CCND1 is altered in 3.17% of gastric adenocarcinoma patients [2].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 is altered in 5.53% of gastric adenocarcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 4 clinical trials for gastric adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain CDK12 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [3].

CDK4 is altered in 1.41% of gastric adenocarcinoma patients [2].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 is altered in 2.19% of gastric adenocarcinoma patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN2A is altered in 8.87% of gastric adenocarcinoma patients [2].

CDKN2A is an inclusion eligibility criterion in 2 clinical trials for gastric adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

CHEK1 is altered in 1.02% of gastric adenocarcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CHEK2 is altered in 0.89% of gastric adenocarcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 4 clinical trials for gastric adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain CHEK2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [3].

CRKL is altered in 0.64% of gastric adenocarcinoma patients [2].

CRKL is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains CRKL status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

CSF1R is altered in 1.3% of gastric adenocarcinoma patients [2].

CSF1R is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CTNNB1 is altered in 4.39% of gastric adenocarcinoma patients [2].

CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

DDX3X is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

DVL1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

EGFR is altered in 5.93% of gastric adenocarcinoma patients [2].

EGFR is an inclusion eligibility criterion in 2 clinical trials for gastric adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain EGFR status and gastric adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].

EPCAM is altered in 0.33% of gastric adenocarcinoma patients [2].

EPCAM is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is altered in 10.08% of gastric adenocarcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 35 clinical trials for gastric adenocarcinoma, of which 30 are open and 5 are closed. Of the trials that contain ERBB2 status and gastric adenocarcinoma as inclusion criteria, 7 are phase 1 (7 open), 4 are phase 1/phase 2 (3 open), 17 are phase 2 (14 open), 3 are phase 2/phase 3 (3 open), and 4 are phase 3 (3 open) [3].

Fam-trastuzumab deruxtecan, pembrolizumab, and trastuzumab have evidence of efficacy in patients with ERBB2 mutation in gastric adenocarcinoma [3].

ERBB3 is altered in 7.73% of gastric adenocarcinoma patients [2].

ERBB3 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EXO1 is altered in 3.81% of gastric adenocarcinoma patients [2].

EXO1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCA is altered in 3.93% of gastric adenocarcinoma patients [2].

FANCA is an inclusion eligibility criterion in 4 clinical trials for gastric adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCA status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [3].

FANCB is altered in 2.86% of gastric adenocarcinoma patients [2].

FANCB is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCC is altered in 0.9% of gastric adenocarcinoma patients [2].

FANCC is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCD2 is altered in 4.75% of gastric adenocarcinoma patients [2].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCE is altered in 2.05% of gastric adenocarcinoma patients [2].

FANCE is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCF is altered in 1.37% of gastric adenocarcinoma patients [2].

FANCF is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCG is altered in 1.0% of gastric adenocarcinoma patients [2].

FANCG is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCI is altered in 2.63% of gastric adenocarcinoma patients [2].

FANCI is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCL is altered in 1.08% of gastric adenocarcinoma patients [2].

FANCL is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCM is altered in 2.86% of gastric adenocarcinoma patients [2].

FANCM is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR1 is altered in 2.18% of gastric adenocarcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 2 clinical trials for gastric adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGFR2 is altered in 5.0% of gastric adenocarcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 4 clinical trials for gastric adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain FGFR2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (2 open) [3].

FGFR3 is altered in 1.99% of gastric adenocarcinoma patients [2].

FGFR3 is an inclusion eligibility criterion in 2 clinical trials for gastric adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FLT1 is altered in 2.13% of gastric adenocarcinoma patients [2].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is altered in 1.34% of gastric adenocarcinoma patients [2].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 is altered in 2.71% of gastric adenocarcinoma patients [2].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FZD1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD10 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD2 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD3 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD4 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD5 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD6 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD7 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD8 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD9 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

GEN1 is altered in 4.76% of gastric adenocarcinoma patients [2].

GEN1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains GEN1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDR is altered in 1.9% of gastric adenocarcinoma patients [2].

KDR is an inclusion eligibility criterion in 2 clinical trials for gastric adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and gastric adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].

KIT is altered in 1.22% of gastric adenocarcinoma patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2D is altered in 11.67% of gastric adenocarcinoma patients [2].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

KRAS is altered in 13.47% of gastric adenocarcinoma patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

LRP5 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP6 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MET is altered in 3.56% of gastric adenocarcinoma patients [2].

MET is an inclusion eligibility criterion in 4 clinical trials for gastric adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain MET status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (2 open) [3].

MLH1 is altered in 1.59% of gastric adenocarcinoma patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH3 is altered in 3.12% of gastric adenocarcinoma patients [2].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A is altered in 1.18% of gastric adenocarcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 2 clinical trials for gastric adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain MRE11A status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MSH2 is altered in 3.25% of gastric adenocarcinoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH3 is altered in 6.48% of gastric adenocarcinoma patients [2].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 is altered in 2.52% of gastric adenocarcinoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MST1R is altered in 3.15% of gastric adenocarcinoma patients [2].

MST1R is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MTAP is altered in 1.25% of gastric adenocarcinoma patients [2].

MTAP is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MTOR is altered in 3.96% of gastric adenocarcinoma patients [2].

MTOR is an inclusion eligibility criterion in 2 clinical trials for gastric adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain MTOR status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].

MYC is altered in 4.85% of gastric adenocarcinoma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NBN is altered in 1.77% of gastric adenocarcinoma patients [2].

NBN is an inclusion eligibility criterion in 4 clinical trials for gastric adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain NBN status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [3].

NRAS is altered in 0.44% of gastric adenocarcinoma patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

NRG1 is altered in 0.97% of gastric adenocarcinoma patients [2].

NRG1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRG1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK1 is altered in 2.28% of gastric adenocarcinoma patients [2].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK2 is altered in 1.4% of gastric adenocarcinoma patients [2].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK3 is altered in 3.3% of gastric adenocarcinoma patients [2].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PALB2 is altered in 1.51% of gastric adenocarcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 4 clinical trials for gastric adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain PALB2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [3].

PCNA is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is altered in 1.33% of gastric adenocarcinoma patients [2].

PDGFRA is an inclusion eligibility criterion in 2 clinical trials for gastric adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain PDGFRA status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].

PDGFRB is altered in 1.79% of gastric adenocarcinoma patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CA is altered in 9.52% of gastric adenocarcinoma patients [2].

PIK3CA is an inclusion eligibility criterion in 3 clinical trials for gastric adenocarcinoma, of which 1 is open and 2 are closed. Of the trials that contain PIK3CA status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 2 are phase 2 (1 open) [3].

PIK3CB is altered in 1.62% of gastric adenocarcinoma patients [2].

PIK3CB is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CB status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PIK3CG is altered in 3.5% of gastric adenocarcinoma patients [2].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CG status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PIK3R1 is altered in 2.02% of gastric adenocarcinoma patients [2].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3R1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PIK3R2 is altered in 1.23% of gastric adenocarcinoma patients [2].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3R2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PMS1 is altered in 1.66% of gastric adenocarcinoma patients [2].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 is altered in 2.09% of gastric adenocarcinoma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLD1 is altered in 5.0% of gastric adenocarcinoma patients [2].

POLD1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is altered in 2.58% of gastric adenocarcinoma patients [2].

POLE is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PTEN is altered in 4.28% of gastric adenocarcinoma patients [2].

PTEN is an inclusion eligibility criterion in 3 clinical trials for gastric adenocarcinoma, of which 1 is open and 2 are closed. Of the trials that contain PTEN status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (1 open) [3].

RAD50 is altered in 1.61% of gastric adenocarcinoma patients [2].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51 is altered in 0.26% of gastric adenocarcinoma patients [2].

RAD51 is an inclusion eligibility criterion in 3 clinical trials for gastric adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAD51 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

RAD51B is an inclusion eligibility criterion in 2 clinical trials for gastric adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51B status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD51C is altered in 0.8% of gastric adenocarcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 4 clinical trials for gastric adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD51C status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [3].

RAD51D is altered in 0.32% of gastric adenocarcinoma patients [2].

RAD51D is an inclusion eligibility criterion in 3 clinical trials for gastric adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAD51D status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

RAD54L is altered in 0.61% of gastric adenocarcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 3 clinical trials for gastric adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAD54L status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

RAF1 is altered in 1.79% of gastric adenocarcinoma patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET is altered in 3.52% of gastric adenocarcinoma patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC2 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC3 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC4 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC5 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RICTOR is altered in 3.11% of gastric adenocarcinoma patients [2].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains RICTOR status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ROS1 is altered in 2.76% of gastric adenocarcinoma patients [2].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA2 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA3 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA4 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPTOR is altered in 1.78% of gastric adenocarcinoma patients [2].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains RPTOR status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

SLX4 is altered in 4.13% of gastric adenocarcinoma patients [2].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SMARCA4 is altered in 5.93% of gastric adenocarcinoma patients [2].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SSBP1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is altered in 53.66% of gastric adenocarcinoma patients [2].

TP53 is an inclusion eligibility criterion in 3 clinical trials for gastric adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [3].

TSC1 is altered in 1.92% of gastric adenocarcinoma patients [2].

TSC1 is an inclusion eligibility criterion in 2 clinical trials for gastric adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain TSC1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].

TSC2 is altered in 2.82% of gastric adenocarcinoma patients [2].

TSC2 is an inclusion eligibility criterion in 2 clinical trials for gastric adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain TSC2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].

UGT1A1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains UGT1A1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

VHL is altered in 0.56% of gastric adenocarcinoma patients [2].

VHL is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

WNT1 is an inclusion eligibility criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].